Effect of Melatonin on Oxidative Stress in Obese Adults (MELASTRESSOB) (MELASTRESSOB)
Primary Purpose
Obesity
Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
BWRP
BWRP + melatonin
Sponsored by
About this trial
This is an interventional treatment trial for Obesity focused on measuring Obesity, Melatonin, Oxidative stress, Adulthood
Eligibility Criteria
Inclusion Criteria: body mass index > 30 kg/m2 absence of concomitant relevant diseases, apart severe obesity hospitalized for a period of integrated metabolic rehabilitation Exclusion Criteria: - concomitant relevant diseases
Sites / Locations
- Istituto Auxologico Italiano IRCCS, Site PiancavalloRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Integrated multidisciplinary body weight reduction program (BWRP)
Integrated multidisciplinary body weight reduction program (BWRP) + melatonin
Arm Description
Outcomes
Primary Outcome Measures
dROMS (reactive oxygen species) during physical exercise protocol
Change in dROMS
Malondialdehyde (MDA) during physical exercise protocol
Change in malondialdehyde
Ratio of oxidized/reduced GSH (glutathione) during physical exercise protocol
Change in ratio of oxidized/reduced GSH (glutathione)
Plasma iron-reducing capacity (FRAP) during physical exercise protocol
Change in plasma iron-reducing capacity (FRAP)
Secondary Outcome Measures
Melatonin concentration
Change in melatonin concentration
Full Information
NCT ID
NCT05759429
First Posted
February 26, 2023
Last Updated
February 26, 2023
Sponsor
Istituto Auxologico Italiano
1. Study Identification
Unique Protocol Identification Number
NCT05759429
Brief Title
Effect of Melatonin on Oxidative Stress in Obese Adults (MELASTRESSOB)
Acronym
MELASTRESSOB
Official Title
Effect of Melatonin on Oxidative Stress in Obese Adults Undergoing an Acute Exercise Session
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 29, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Istituto Auxologico Italiano
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The present research project aims to evaluate oxidative stress in a cohort of obese adults, subjected to an in-hospital 3-week multidisciplinary body weight reduction program (BWRP) with or without melatonin. Our hypothesis is that melatonin, administered to the obese subject, could be effective in reducing the oxidative stress associated with physical exercise (acute).
Specifically, the main objective will be to investigate a difference in the mean levels of some peripheral oxidative stress markers at their peak during an acute exercise session in the two groups (primary endpoint).
Secondly, the possible pre-post difference (baseline vs end of treatment) of the peak of each oxidative stress marker between the two groups will be evaluated (secondary endpoint
Detailed Description
Materials and methods 20 obese subjects (F/M = 10/10; age range 18-40 years; body mass index, BMI > 30 kg/m2), hospitalized for a period of integrated metabolic rehabilitation (BWRP) at the Division of Metabolic Diseases, Istituto Auxologico Italiano, Piancavallo (VB), Italy.
After verifying the inclusion/exclusion criteria, including the absence of other relevant pathologies apart from obesity, we will proceed with the collection of clinical data (heart rate, blood pressure, body temperature) and anthropometric data (weight, height, BMI, waist circumference, hip circumference), including assessment of body composition with bio-impedancemetry.
According to a randomized scheme, with the only constraint of maintaining a 1/1 ratio for sex, the subjects will undergo one of the following interventions:
Integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education;
Integrated multidisciplinary BWRP (as above) combined with melatonin. Melatonin will be administered during 15 consecutive days of our standard BWRP, after dinner, and 2-3 hours before bedtime. The first dose will be administered on the same evening of the day in which the incremental exercise (test 1, baseline G0) will be performed, necessary to establish the execution conditions of test 2.
The acute exercise session (test 2, described below) will be performed at D1 and D15 (days 1-15 of BWRP).
Each subject will conduct the following exercise protocols:
Incremental exercise (4 min rest, 3 min walk at 4 km/h and 0% incline followed by 1% incline and speed increments of 0.5 km/h every minute), breathing a mixture composed of 21 % O2 in nitrogen (ambient air, O2-N2); this exercise is necessary to establish the execution conditions of test 2, which represents the effective exercise that will be performed before and after the intervention and during which the blood samples described below will be taken;
Moderate intensity constant load exercise, at a load corresponding to 60% of the aerobic threshold, determined during the above incremental exercise, conducted for 30 minutes or until voluntary exhaustion, performed at D1 and D15.
All tests will be monitored and supervised by dedicated personnel. For each of the two acute exercise sessions (i.e., before starting the BWRP-G1 and after the BWRP-G15 intervention), four blood draws will be taken: in baseline conditions (pre-exercise), immediately at the end of the 'exercise, and 60-120 minutes after the end of exercise (T0', T30', T90' and T150', respectively), to identify the peak of each marker.
In plasma/serum samples taken basally (T0'), at the end of exercise (T30'), 60' post (T90'), and 120' post (T150') after the end of the exercise, a panel of markers will be determined peripheral oxidative stress. In particular:
dROMS (reactive oxygen species)
MDA (malondialdehyde)
Oxidized/reduced GSH (glutathione).
FRAP (plasma iron-reducing capacity, which corresponds to the total antioxidant capacity);
melatonin and tryptophan metabolites. TNF-α, IL-6, and IL-8 levels will be determined in plasma/serum samples taken basally (T0') and at the end of physical exercise (T30'). Finally, the basal glucometabolic profile (glucose, insulin, HOMA-IR, glycated Hb, triglycerides, total cholesterol, LDL, HDL, and hsPCR) will be analyzed in the basal plasma/serum samples (T0').
Approval of the protocol by the Ethics Committee will be required; informed consent will be collected from all participants.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity, Melatonin, Oxidative stress, Adulthood
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Integrated multidisciplinary body weight reduction program (BWRP)
Arm Type
Active Comparator
Arm Title
Integrated multidisciplinary body weight reduction program (BWRP) + melatonin
Arm Type
Active Comparator
Intervention Type
Other
Intervention Name(s)
BWRP
Intervention Description
Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education
Intervention Type
Other
Intervention Name(s)
BWRP + melatonin
Intervention Description
Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP and melatonin (4 mg/die), administered 2-3 hours before bedtime
Primary Outcome Measure Information:
Title
dROMS (reactive oxygen species) during physical exercise protocol
Description
Change in dROMS
Time Frame
Baseline (T0'), after 30 minutes of the physical exercise protocol (T30') and at T90' and T120' at day 1 and day 15 of the intervention
Title
Malondialdehyde (MDA) during physical exercise protocol
Description
Change in malondialdehyde
Time Frame
Baseline and after 30, 60, 90 and 120 minutes of the physical exercise protocol at day 15 of the intervention
Title
Ratio of oxidized/reduced GSH (glutathione) during physical exercise protocol
Description
Change in ratio of oxidized/reduced GSH (glutathione)
Time Frame
Baseline (T0'), after 30 minutes of the physical exercise protocol (T30') and at T90' and T120' at day 1 and day 15 of the intervention
Title
Plasma iron-reducing capacity (FRAP) during physical exercise protocol
Description
Change in plasma iron-reducing capacity (FRAP)
Time Frame
Baseline (T0'), after 30 minutes of the physical exercise protocol (T30') and at T90' and T120' at day 1 and day 15 of the intervention
Secondary Outcome Measure Information:
Title
Melatonin concentration
Description
Change in melatonin concentration
Time Frame
Baseline (T0') and after 30 minutes of the physical exercise protocol (T30') at day 1 and day 15 of the intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
body mass index > 30 kg/m2
absence of concomitant relevant diseases, apart severe obesity
hospitalized for a period of integrated metabolic rehabilitation
Exclusion Criteria:
- concomitant relevant diseases
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alessandro Sartorio, MD
Phone
+390261911
Ext
2426
Email
sartorio@auxologico.it
First Name & Middle Initial & Last Name or Official Title & Degree
Luca Grappiolo, Dr.
Phone
+390261911
Ext
2894
Email
luca.grappiolo@auxologico.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alessandro Sartorio, MD
Organizational Affiliation
Istituto Auxologico Italiano
Official's Role
Principal Investigator
Facility Information:
Facility Name
Istituto Auxologico Italiano IRCCS, Site Piancavallo
City
Oggebbio
State/Province
Verbania
ZIP/Postal Code
28824
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessandro Sartorio
Phone
+390261911
Ext
2426
Email
sartorio@auxologico.it
12. IPD Sharing Statement
Learn more about this trial
Effect of Melatonin on Oxidative Stress in Obese Adults (MELASTRESSOB)
We'll reach out to this number within 24 hrs